NEW YORK (GenomeWeb News) — Investment bank Cowen & Co. today downgraded shares of Illumina to "Neutral" from "Outperform."
Reuters today reported that Cowen said the shares "appear reasonably valued, noting the firm's shares were up 154 percent year-to-date."
Reuters reported that the brokerage said "many investors agree with its view that Illumina's high-throughput genotyping technology is best in class."
Registering provides access to this and other free content.
Already have an account?Login Now.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.